In humans this protein is encoded by the MOG gene. MOGAD is an inflammatory demyelinating disease that is distinct from multiple sclerosis and antiAQP4+. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is the most recently defined inflammatory demyelinating disease of the central nervous system (CNS). In his lab, they use genetically modified mice to model these neuroimmunological interactions and then develop strategies to re-educate the immune system towards a better outcome. Myelin oligodendrocyte glycoprotein ( MOG) is a glycoprotein believed to be important in the myelination of nerves in the central nervous system (CNS). MOG is located on the outer surface of the myelin sheath. Myelin oligodendrocyte glycoprotein ( MOG) is a glycoprotein believed to be important in the myelination of nerves in the central nervous system (CNS). This includes autoimmune diseases, such as neuromyelitis optica, in which the immune system is aberrantly responding to a harmless trigger, as well as Parkinsons and Alzheimer's disease in which the immune system might be reacting to a trigger in the neural environment. Published in The Lancet Neurology, a convened panel of pediatric and adult neurologists, neuroimmunologists, and researchers have proposed a new diagnostic criteria for myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) that includes the presence of MOG-IgG as a core criterion. Less common ophthalmic manifestations reported in MOGAD include uveitis, macular neuro-retinopathy, neuroretinitis, retinopathy secondary to venous stasis and increased intracranial pressure. Levy is focused on understanding how the immune system and the nervous system interact to cause disease. Levy is the principal investigator on several clinical studies and drug trials for all of these conditions.Īppointed the Research Director of the Division of Neuroimmunology & Neuroinfectious Disease at Massachusetts General Hospital, Dr. MOG antibody disease (MOGAD) is a recently coined neuro-inflammatory condition that preferentially causes inflammation in the optic nerve but can also cause. Levy has a special interest in patients with superficial siderosis of the central nervous system. In addition to neuroimmunology clinics, Dr. Levy specializes in taking care of patients with rare neuroimmunological diseases including neuromyelitis optica, transverse myelitis, MOG antibody disease, acute disseminated encephalomyelitis and optic neuritis. Levy was appointed to the faculty as Assistant Professor at Johns Hopkins where he started the Neuromyelitis Optica Clinic and Research Laboratory and in 2019 he moved to the Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.Ĭlinically, Dr. Levy completed his Johns Hopkins internship in the Osler Medicine program, residency in the Johns Hopkins Neurology program and a fellowship in Neuroimmunology at Johns Hopkins University. He completed the MD/PhD program at Baylor College of Medicine (Houston, TX) with a focus on neuroscience. Michael Levy, MD, PhD, is the Research Director of the Division of Neuroimmunology & Neuroinfectious Disease. Billing, Insurance & Financial Assistanceĭr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |